ArticleInvestigative ophthalmology & visual science2026
Longitudinal Multi-Omics Profiling of Aqueous Humor Implicates GALNS Depletion as a Pro-Fibrotic Mediator of Anti-VEGF Therapy in PDR.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Preoperative anti-vascular endothelial growth factor (VEGF) therapy in proliferative diabetic retinopathy (PDR) may exacerbate fibrovascular contraction, posing significant challenges. This study aims to characterize proteo-metabolomic changes induced by anti-VEGF therapy, validate key candidates on orthogonal analytical platforms, and provide functional evidence for the lead molecule. Methods: Aqueous humor from 25 patients with PDR with simple vitreous hemorrhage (VH; n = 13) or VH with tractional retinal detachment (VH + TRD; n = 12) underwent data-independent acquisition (DIA) proteomics and widely targeted metabolomics before and 7 days after intravitreal aflibercept. Molecules altered in both cross-sectional and longitudinal comparisons were classified as "aggravation-type" or "improvement-type." Aggravation-type molecules were validated by parallel reaction monitoring/selected reaction monitoring (PRM/SRM) in an independent cohort (cataract controls, n = 10; simple VH, n = 5; VH + TRD, n = 5), and GALNS was functionally assessed by siRNA knockdown in fibroblasts. Results: Intersection analysis identified 38 molecules (5 proteins and 33 metabolites): 35 improvement-type and 3 aggravation-type (CAST, GALNS, and 3-hydroxypropanoic acid [3-HPA]). Independent validation using PRM proteomics and SRM metabolomics confirmed that only GALNS was robustly validated across both cross-sectional (P = 0.016) and longitudinal (P = 0.049) comparisons, whereas CAST and 3-HPA did not reach statistical significance in validation. GALNS exhibited a biphasic pattern-elevated in PDR relative to cataract controls yet depleted in VH + TRD and further declined post-treatment. GALNS knockdown in fibroblasts upregulated α-SMA and collagen I, accelerated migration, and enhanced contractility. Conclusions: This multi-omics study, reinforced by independent validation, reveals GALNS depletion as a potential pro-fibrotic molecule following anti-VEGF therapy in PDR, offering a promising candidate for perioperative risk stratification. CAST and 3-HPA remain exploratory candidates requiring validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.